Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-12 01:17 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
Clozapine Versus Amisulpride in Treatment-resistant Schizophrenia Patients
NCT01448499 · Geha Mental Health Center · NA · withdrawn · last registry update 2015-12-09 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
No reason was published
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | The registry record gives no reason | – | Registry record, Geha Mental Health Center |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against HTR2A within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2016-11-22Phase 3 first posted: ACADIA Pharmaceuticals Inc., Pimavanserin + Placebo (NCT02970292)
- 2016-11-01Also stopped (terminated): Thorax-Kärlkliniken, Dexmedetomidine + Haloperidol (NCT01140529)
- 2016-10-27Results posted on the registry: Yale University, ziprasidone + placebo (NCT00635700)
- 2016-08-22Results posted on the registry: Sumitomo Pharma America, Inc., Lurasidone (NCT01575561)
- 2016-08-11Phase 3 first posted: EMS, ketoprofen and cyclobenzaprine association with caffeine + Cyclobenzaprine with caffeine (NCT02862977)
- 2016-07-26Results posted on the registry: Sumitomo Pharma America, Inc., Lurasidone + Placebo (NCT01358357)
- 2016-07-12Phase 3 first posted: Tonix Pharmaceuticals, Inc., TNX-102 SL Tablet, 2.8 mg + Placebo SL Tablet (NCT02829814)
- 2016-06-27Phase 3 first posted: Takeda, Cyclobenzaprine HCl + Placebo (NCT02814565)
- 2016-06-23Phase 3 first posted: University of Zurich, Phenobarbital + Chlorpromazine (NCT02810782)
- 2016-06-01Results posted on the registry: New York State Psychiatric Institute, Standard of Care + Ketamine (NCT01833897)
- 2016-05-03Also stopped (withdrawn): Eurofarma Laboratorios S.A., meloxicam/cyclobenzaprine hydrochloride + meloxicam - Movatec® (NCT01587508)
- 2016-04-25Results posted on the registry: Centre for Addiction and Mental Health, Haloperidol + Fluphenazine (NCT02203786)
- 2016-04-20Also stopped (terminated): Lynn Henry, Cyclobenzaprine (NCT01921296)
- 2016-04-07Phase 3 first posted: Lakshmi N Yatham, lurasidone (NCT02731612)
- 2016-03-17Also stopped (withdrawn): Eric E. Prommer, Haloperidol + Placebo (NCT01684969)
- 2016-02-25Phase 3 first posted: Supernus Pharmaceuticals, Inc., SPN-810 (NCT02691182)
- 2016-02-25Results posted on the registry: Sumitomo Pharma America, Inc., Lurasidone 20 mg daily + Lurasidone (NCT01911442)
- 2016-02-08Results posted on the registry: University of Pittsburgh, Injectable Risperidone (Consta) or oral antipsychotic (NCT00177164)
- 2016-02-05Results posted on the registry: Northwell Health, Ziprasidone + aripiprazole, quetiapine, or risperidone (NCT01844700)
- 2016-02-05Also stopped (terminated): Northwell Health, Ziprasidone + aripiprazole, quetiapine, or risperidone (NCT01844700)
- 2016-01-08Results posted on the registry: Sumitomo Pharma America, Inc., Lurasidone + Lurasidone 80 mg once daily initially rerandomized either to 80 mg or 160 mg at week 2 (NCT01821378)
- 2015-12-30Phase 3 first posted: Tanta University, Cyclobenzaprine + Calcium Carbonate (NCT02642861)
- 2015-12-01Phase 3 first posted: Supernus Pharmaceuticals, Inc., SPN-810 (18 mg) + SPN-810 (36 mg) (NCT02618434)
- 2015-12-01Phase 3 first posted: Supernus Pharmaceuticals, Inc., SPN-810 (18 mg) + SPN-810 (36 mg) (NCT02618408)
- 2015-10-28Phase 3 first posted: Tonix Pharmaceuticals, Inc., TNX-102 SL Tablet 2.8 mg (NCT02589275)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision